HealthDay on MSN2h
FDA Approval Expands Earlier Use of Enhertu for Metastatic Breast Cancer
The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...
Competitive Intelligence in Breast Cancer: Tracking the Evolving HR+ HER2-ve Breast Cancer Landscape
HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone ...
2AZN : AstraZeneca Blames 'Toxic' Climate As It Walks Away from Over
AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...
pharmaphorum16h
Report says AZ's UK plant decision is not just about funding
That includes the recent decision to reject NHS use of AZ and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for HER2-low ...
Daily18h
Daiichi Sankyo names Hiroyuki Okuzawa as CEO
Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive ...
AstraZeneca Stock Rally Will be Tested by Answers on China Probe
A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...